See more : Hangzhou Hota M&E Holdings Co., Ltd. (001225.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Senzime AB (publ) (SEZI.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senzime AB (publ), a leading company in the Medical – Devices industry within the Healthcare sector.
- Workday, Inc. (WDAY) Income Statement Analysis – Financial Results
- Shunten International (Holdings) Limited (0932.HK) Income Statement Analysis – Financial Results
- Katana Capital Limited (KAT.AX) Income Statement Analysis – Financial Results
- Chobi Company Limited (001550.KS) Income Statement Analysis – Financial Results
- Daido Kogyo Co., Ltd. (6373.T) Income Statement Analysis – Financial Results
Senzime AB (publ) (SEZI.ST)
About Senzime AB (publ)
Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.75M | 14.03M | 10.98M | 9.34M | 6.71M | 3.21M | 189.00K | 1.63M | 152.63K | 541.16K | 1.24M | 298.34K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 27.42M | 18.43M | 15.90M | 17.24M | 15.25M | 8.44M | 745.00K | 526.00K | 1.73M | 2.29M | 3.33M | -398.77K | -1.82M | -1.71M | -1.68M |
| Gross Profit | 8.34M | -4.40M | -4.92M | -7.90M | -8.54M | -5.23M | -556.00K | 1.10M | -1.58M | -1.75M | -2.09M | 697.12K | 1.82M | 1.71M | 1.68M |
| Gross Profit Ratio | 23.32% | -31.32% | -44.84% | -84.60% | -127.24% | -162.63% | -294.18% | 67.69% | -1,033.34% | -323.22% | -169.26% | 233.66% | 0.00% | 0.00% | 0.00% |
| Research & Development | 19.36M | 19.46M | 12.53M | 8.19M | 4.79M | 3.43M | 179.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 45.11M | 44.34M | 28.18M | 31.15M | 10.65M | 7.97M | 6.00M | 5.20M | 2.66M | 1.75M | 1.01M | 3.38M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 77.68M | 70.05M | 39.53M | 16.05M | 3.88M | 2.35M | 1.56M | 1.30M | 889.12K | 702.86K | 522.62K | 86.70K | 0.00 | 0.00 | 0.00 |
| SG&A | 122.79M | 114.39M | 67.71M | 31.15M | 14.53M | 10.32M | 7.56M | 6.51M | 3.55M | 2.45M | 1.53M | 3.46M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | -327.00K | -78.00K | 0.00 | 13.36M | 11.22M | 4.91M | 4.01M | 2.47M | 2.09M | 2.07M | 5.12M | 3.93M | 3.97M | 3.31M |
| Operating Expenses | 141.52M | 133.52M | 80.16M | 39.33M | 27.89M | 21.53M | 12.47M | 10.51M | 6.02M | 4.55M | 3.60M | 5.12M | 3.93M | 3.97M | 3.31M |
| Cost & Expenses | 169.57M | 151.95M | 96.06M | 56.57M | 43.14M | 29.98M | 13.21M | 11.04M | 7.75M | 6.84M | 6.93M | 4.72M | 2.11M | 2.26M | 1.63M |
| Interest Income | 999.00K | 430.00K | 79.00K | 122.00K | 34.00K | 48.00K | 0.00 | 0.00 | 17.33K | 111.37K | 102.61K | 52.06K | 108.48K | 24.27K | 46.72K |
| Interest Expense | 798.00K | 430.00K | 79.00K | 122.00K | 3.00K | 0.00 | 2.00K | 1.00K | 2.47K | 5.75K | 9.57K | 24.71K | 95.78K | 121.61K | 138.88K |
| Depreciation & Amortization | 17.54M | 13.86M | 10.99M | 11.90M | 11.19M | 5.50M | 357.00K | 678.00K | 1.25M | 1.32M | 1.13M | 859.42K | 17.54K | 18.39K | 134.97K |
| EBITDA | -118.82M | -120.05M | -73.21M | -36.96M | -23.04M | -21.27M | -12.67M | -8.73M | -6.33M | -4.87M | -4.45M | -3.51M | -1.99M | -2.21M | -1.45M |
| EBITDA Ratio | -332.33% | -843.20% | -667.08% | -390.59% | -357.10% | -661.61% | -6,702.65% | -536.43% | -4,145.52% | -899.52% | -360.63% | -1,175.95% | 0.00% | 0.00% | 0.00% |
| Operating Income | -133.75M | -133.91M | -84.19M | -48.87M | -36.43M | -26.76M | -13.03M | -9.41M | -7.60M | -6.30M | -5.69M | -4.42M | -2.11M | -2.26M | -1.63M |
| Operating Income Ratio | -374.07% | -954.15% | -766.77% | -523.36% | -542.86% | -832.64% | -6,891.53% | -578.07% | -4,977.80% | -1,163.68% | -460.79% | -1,481.47% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.41M | -453.00K | -98.00K | -1.76M | -148.00K | 62.00K | -2.00K | -1.00K | 15.00K | 105.61K | 93.04K | 27.35K | 12.69K | -97.34K | -92.16K |
| Income Before Tax | -137.16M | -134.36M | -84.29M | -48.99M | -36.43M | -26.76M | -13.03M | -9.41M | -7.58M | -6.19M | -5.60M | -4.39M | -2.10M | -2.35M | -1.72M |
| Income Before Tax Ratio | -383.62% | -957.37% | -767.66% | -524.71% | -542.88% | -832.70% | -6,892.59% | -578.13% | -4,968.07% | -1,144.16% | -453.26% | -1,472.30% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -3.01M | -1.66M | -2.15M | -1.55M | -2.76M | -1.14M | 2.00K | 1.00K | -2.05K | -105.61K | -93.04K | -27.35K | -12.69K | 97.34K | 92.16K |
| Net Income | -134.15M | -132.70M | -82.14M | -47.45M | -33.68M | -25.62M | -13.03M | -9.41M | -7.58M | -6.19M | -5.60M | -4.39M | -2.10M | -2.35M | -1.72M |
| Net Income Ratio | -375.20% | -945.56% | -748.11% | -508.14% | -501.79% | -797.17% | -6,892.59% | -578.13% | -4,966.72% | -1,144.16% | -453.26% | -1,472.30% | 0.00% | 0.00% | 0.00% |
| EPS | -1.45 | -1.96 | -1.30 | -0.83 | -0.66 | -0.59 | -0.33 | -0.33 | -0.49 | -0.43 | -0.43 | -0.38 | -0.23 | -0.32 | -0.32 |
| EPS Diluted | -1.45 | -1.96 | -1.30 | -0.83 | -0.66 | -0.57 | -0.33 | -0.33 | -0.49 | -0.43 | -0.43 | -0.38 | -0.23 | -0.32 | -0.32 |
| Weighted Avg Shares Out | 92.27M | 67.55M | 63.36M | 56.98M | 50.79M | 43.77M | 39.92M | 28.19M | 15.32M | 14.54M | 13.03M | 11.51M | 9.21M | 7.36M | 5.42M |
| Weighted Avg Shares Out (Dil) | 92.27M | 67.55M | 63.36M | 56.98M | 50.79M | 44.77M | 40.05M | 28.29M | 15.42M | 14.54M | 13.03M | 11.51M | 9.21M | 7.36M | 5.42M |
Source: https://incomestatements.info
Category: Stock Reports